Roelants V, Goulios C, Beckers C, Jamar F
Center of Nuclear Medicine, University of Louvain Medical School, Brussels, Belgium.
J Nucl Med. 1998 Jun;39(6):1007-12.
Iodine-131-metaiodobenzylguanidine (MIBG) scintigraphy is a reliable method used to diagnose pheochromocytoma. Although the adrenal medulla usually is not visualized, faint uptake can be observed in 16% of the patients 48-72 hr after injection of 18.5-37 MBq 131I-MIBG. We recently observed an increase in the frequency of visualization of the adrenal medulla in patients injected with 74 MBq 131I-MIBG. Therefore, we retrospectively evaluated the pattern of uptake and potential changes between 1984 and 1994.
Scintigraphic data from 103 patients referred for suspected pheochromocytoma were reviewed randomly. Data from 19 patients with medullary thyroid carcinoma were analyzed separately. Patients were injected with 74 MBq 131I-MIBG and imaged at 24 hr postinjection, 48 hr postinjection, or both. Adrenal uptake was scored visually as 0 (no visible uptake) and 1 (uptake just visible) to 4 (most intense activity in the picture). Semiquantitative indicies were evaluated for discriminating between normal adrenal medullae and pheochromocytomas. Twenty-seven pheochromocytomas were surgically proven in 25 patients.
A visual score > or =3 was noted in 81% and 90% of the pheochromocytomas at 24 hr and 48 hr postinjection, respectively. From 1984 to 1988, 16% and 31% of adrenal medullae were seen at 24 and 48 hr postinjection, respectively, whereas from 1989 to 1994, 56% and 73% were visualized at 24 and 48 hr postinjection, respectively. Before 1989, the best cutoff criterion to identify a pheochromocytoma, determined from receiver operating characteristic curve analysis, was a score > or =1 at 24 hr and > or =3 at 48 hr postinjection, with a sensitivity and specificity of 92% and 84% at 24 hr and 92% and 99% at 48 hr postinjection. From 1989, the best cutoff was a score > or =3 at both imaging sessions, with a sensitivity and specificity of 82% and 100% at 24 hr and 100% and 97% at 48 hr postinjection. Among the semiquantitative indicies, the adrenal-to-liver and adrenal-to-heart ratios were the best discriminators between normal and pathological adrenals. They were, however, of little use because of the overlap between normal adrenal medullae and pheochromocytomas.
The high rate of visualization of the normal adrenal medulla in this study was related to the larger-than-usual injected dose (74 MBq). Over recent years, however, this rate has been increasing, possibly because of the increased specific activity of 31I-MIBG. Adequate interpretation should take into account that a faint or definite uptake may be visible in more than 50% of normal adrenal medullae.
碘-131-间碘苄胍(MIBG)闪烁扫描术是用于诊断嗜铬细胞瘤的可靠方法。虽然肾上腺髓质通常不显影,但在注射18.5 - 37 MBq 131I-MIBG后48 - 72小时,16%的患者可观察到轻微摄取。我们最近观察到,注射74 MBq 131I-MIBG的患者中肾上腺髓质显影频率增加。因此,我们回顾性评估了1984年至1994年间的摄取模式及潜在变化。
随机回顾了103例因疑似嗜铬细胞瘤而转诊患者的闪烁扫描数据。对19例甲状腺髓样癌患者的数据进行了单独分析。患者注射74 MBq 131I-MIBG,并在注射后24小时、48小时或两个时间点进行成像。肾上腺摄取通过视觉评分,0分表示无可见摄取,1分表示摄取刚刚可见,直至4分表示图像中活性最强。评估了半定量指标以区分正常肾上腺髓质和嗜铬细胞瘤。25例患者中的27个嗜铬细胞瘤经手术证实。
分别在注射后24小时和48小时,81%和90%的嗜铬细胞瘤视觉评分为≥3分。1984年至1988年,分别在注射后24小时和48小时观察到16%和31%的肾上腺髓质,而1989年至1994年,分别在注射后24小时和48小时观察到56%和73%的肾上腺髓质。1989年前,根据受试者操作特征曲线分析确定的识别嗜铬细胞瘤的最佳截断标准为注射后24小时评分≥1分,48小时评分≥3分,注射后24小时的敏感性和特异性分别为92%和84%,48小时为92%和99%。从1989年起,最佳截断值为两个成像时间点评分均≥3分,注射后24小时的敏感性和特异性分别为82%和100%,48小时为100%和97%。在半定量指标中,肾上腺与肝脏及肾上腺与心脏的比值是区分正常和病理性肾上腺的最佳指标。然而,由于正常肾上腺髓质和嗜铬细胞瘤之间存在重叠,它们的作用不大。
本研究中正常肾上腺髓质的高显影率与注射剂量大于通常剂量(74 MBq)有关。然而,近年来该比率一直在增加,可能是由于131I-MIBG比活度增加。充分的解读应考虑到超过50%的正常肾上腺髓质可能可见轻微或明确的摄取。